Agenus (AGEN)
NASDAQ:AGEN
Want to see AGEN full AI Analyst Report?
AGEN Stock Chart & Stats
$4.79
-$0.06(-1.69%)
At close: 4:00 PM EST
$4.79
-$0.06(-1.69%)
Day’s Range― - ―
52-Week Range$2.71 - $7.34
Previous CloseN/A
Volume199.21K
Average Volume (3M)840.89K
Market Cap
$143.99M
Enterprise Value$475.89M
Total Cash (Recent Filing)$3.00M
Total Debt (Recent Filing)$334.90M
Price to Earnings (P/E)―
Beta2.44
Next Earnings
May 11, 2026EPS Estimate
2.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding38,398,354
10 Day Avg. Volume1,532,657
30 Day Avg. Volume840,894
Financial Highlights & Ratios
PEG Ratio-8.12
Price to Book (P/B)-0.34
Price to Sales (P/S)0.82
P/FCF Ratio-0.59
Enterprise Value/Market Cap3.30
Enterprise Value/Revenue4.17
Enterprise Value/Gross Profit11.68
Enterprise Value/Ebitda6.69
Forecast
1Y Price Target
$23.00Price Target Upside380.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.1
Revenue Forecast (FY)$232.45M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Regulatory PotentialMaturing clinical data for the bot/bal therapy demonstrate durable anti-tumor activity and improved survival in treatment-resistant colorectal cancer, supporting the case for regulatory filings and a differentiated treatment profile.
Real-world Evidence And Commercial ReadinessEarly access and named-patient programs are generating incremental revenue and real-world usage data that can strengthen regulatory and payer discussions while increasing physician familiarity.
Strategic Partnership And Manufacturing SupportCollaboration with Zydus provided a significant non-dilutive cash infusion and dedicated manufacturing capacity, reducing financing pressure and enabling trial and regulatory readiness.
Bears Say
Clinical Program Execution RiskThe registrational Phase 3 program depends on activating many international sites and sustained patient enrollment, creating execution risk that could delay development timelines or commercialization.
Financing Risk From Limited CashLimited cash on hand prior to the partner transaction created financing risk for ongoing development, leaving programs vulnerable if additional funding is delayed.
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $2.71 and its highest was $7.34 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is $143.99M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is May 11, 2026 which is in 3 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Mar 16, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$1.043 by $0.743.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is 2.1.
How many shares outstanding does Agenus have?
Agenus has 38,398,354 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -$0.3 in its last earnings report, beating expectations of -$1.043. Following the earnings report the stock price went up 6.129%.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (380.17% Upside)
$23.00 (380.17% Upside)
Blogger Sentiment
Bullish
AGEN Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 23.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
130.28%
12-Months-Change
Fundamentals
Return on Equity
-0.04%
Trailing 12-Months
Asset Growth
0.23%
Trailing 12-Months
Company Description
Agenus
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
AGEN Stock 12 Month Forecast
Average Price Target
$23.00
▲(380.17% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―
Ownership Overview
2.08% Insiders
10.63% Mutual Funds
0.13% Other Institutional Investors
83.28% Public Companies and
Individual Investors